natgillin/translations-raw huggingface dataset:
Treatment of these patients with Sevelamer carbonate Winthrop should only be initiated after careful benefit/risk assessment.
• velikim operativnim zahvatom u gastrointestinalnom traktu Liječenje tih bolesnika lijekom Sevelamer carbonate Winthrop treba započeti tek nakon pomne procjene omjera koristi i rizika.
How to take Sevelamer carbonate Winthrop
Kako uzimati Sevelamer carbonate Winthrop
• upper abdominal pain,
• bol u gornjem dijelu trbuha,
EU/1/14/952/005 90 sachets EU/1/14/952/006 90 sachets (with a dosing spoon)
EU/1/14/952/006 90 vrećica (sa dozirnom žličicom)
For adult patients, serum phosphorus must be monitored and the dose of sevelamer carbonate titrated by 0.8 g three times per day (2.4 g/day) increments every 2-4 weeks until an acceptable serum phosphorus level is reached, with regular monitoring thereafter.
Za odrasle bolesnike, razine fosfora u serumu moraju se pratiti i doza sevelamerkarbonata titrirati u koracima od 0,8 g tri puta na dan (2,4 g/dan) svaka 2 do 4 tjedna dok se ne postigne prihvatljiva razina fosfora u serumu s redovitim praćenjem nakon toga.
Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus > 1.78 mmol/L.
Sevelamer carbonate Winthrop je indiciran i za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu > 1,78 mmol/l.
Package leaflet: Information for the user Sevelamer carbonate Winthrop 0.8 g powder for oral suspension sevelamer carbonate
Uputa o lijeku: Informacije za korisnika Sevelamer carbonate Winthrop 0,8 g prašak za oralnu suspenziju sevelamerkarbonat
Package leaflet: Information for the user Sevelamer carbonate Winthrop 2.4 g powder for oral suspension sevelamer carbonate
Uputa o lijeku: Informacije za korisnika Sevelamer carbonate Winthrop 2,4 g prašak za oralnu suspenziju sevelamerkarbonat
The safety and efficacy of Sevelamer carbonate Winthrop in children over 6 year of age and a BSA >0.75 m2 have been established.
Sigurnost i djelotvornost lijeka Sevelamer carbonate Winthrop u djece starije od 6 godina i s površinom tijela iznad 0,75m2 su ustanovljene.
- Blockage in the intestine (signs include: severe bloating; abdominal pain, swelling or cramps; severe constipation) has been reported.
- blokada crijeva (znakovi uključuju: jaku nadutost, bol u trbuhu, oticanje ili grčeve, teški zatvor) je zabilježena.
Hepatic impairment No studies have been performed in patients with hepatic impairment.
Nisu provedena ispitivanja u bolesnika s oštećenjem funkcije jetre.
Powder for oral suspension 0.8 g powder
Prašak za oralnu suspenziju 0,8 g sevelamerkarbonata
The powder should be dispersed in 60 ml of water per sachet prior to administration.
Prašak iz jedne vrećice mora se prije primjene rastopiti u 60 ml vode.
The safety and effectiveness of sevelamer carbonate in hyperphosphatemic paediatric patients with CKD was evaluated in a multicenter study with a 2-week, randomised, placebo-controlled, fixed dose period (FDP) followed by a 6-month, single-arm, open-label, dose titration period (DTP).
Sigurnost i učinkovitost sevelamerkarbonata u hiperfosfatemičnih pedijatrijskih bolesnika s kroničnom bubrežnom bolesti procijenjene su u multicentričnom ispitivanju s dvotjednim, randomiziranim,
The powder should be dispersed in 30 mL of water per sachet prior to administration.
Prašak iz jedne vrećice mora se prije primjene rastopiti u 30 ml vode.
Sevelamer carbonate Winthrop should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Sevelamer carbonate Winthrop treba primjenjivati u sklopu multiterapijskog pristupa, koji može uključivati nadomjestke kalcija i 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se kontrolirao razvoj bubrežne osteodistrofije.
How to store Sevelamer carbonate Winthrop
Kako čuvati Sevelamer carbonate Winthrop
- Rupture in the intestinal wall (signs include: severe stomach pain, chills, fever, nausea, vomiting, or a tender abdomen) has been reported.
- blokada crijeva (znakovi uključuju: jaku nadutost, bol u trbuhu, oticanje ili grčeve, teški zatvor) je bila zabilježena.
Sevelamer carbonate Winthrop 2.4 g powder for oral suspension
Sevelamer carbonate Winthrop 2,4 g prašak za oralnu suspenziju
Sevelamer carbonate Winthrop 0.8 g powder for oral suspension
Sevelamer carbonate Winthrop 0,8 g prašak za oralnu suspenziju
Sevelamer carbonate Winthrop 2.4 g powder for oral suspension sevelamer carbonate
Sevelamer carbonate Winthrop 2,4 g prašak za oralnu suspenziju sevelamerkarbonat
The study met its primary endpoint, meaning Sevelamer carbonate reduced serum phosphorus by an LS mean difference of 0.90 mg/dL compared to placebo and secondary efficacy endpoints.
Ispitivanje je postiglo mjeru primarnog ishoda, što znači da je sevelamerkarbonat smanjio razinu fosfora u serumu za srednju vrijednost (dobivenu metodom najmanjih kvadrata) razlike od 0,90mg/dL
- The other ingredients are propylene glycol alginate (E405), citrus cream flavour, sodium chloride,
Drugi sastojci su propilenglikolalginat (E405), aroma kreme od citrusa, natrijev klorid, sukraloza i žuti željezov oksid (E172).
Sevelamer carbonate Winthrop 0.8 g powder for oral suspension sevelamer carbonate
Sevelamer carbonate Winthrop 0,8 g prašak za oralnu suspenziju sevelamerkarbonat
• dysphagia
• mučnina
In some cases where Sevelamer carbonate Winthrop should be taken at the same time as another medicine, your doctor may advise you to take this medicine 1 hour before or 3 hours after Sevelamer carbonate Winthrop intake.
liječnik Vam može preporučiti da taj lijek uzmete 1 sat prije ili 3 sata nakon uzimanja lijeka Sevelamer carbonate Winthrop.
It can be an early symptom of a blockage in your intestine.
Zatvor je vrlo česta nuspojava, a može biti rani simptom blokade crijeva.
Propylene glycol alginate (E405) Citrus Cream flavour Sodium chloride Sucralose
6.1 Popis pomoćnih tvari propilenglikolalginat (E405) aroma kreme od citrusa natrijev klorid sukraloza željezov oksid, žuti (E172)
• flatulence.
• proljev,
• The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used to suppress the immune system) may be reduced by Sevelamer carbonate Winthrop.
mofetilmikofenolat i takrolimus (lijekovi koji se primjenjuju za potiskivanje imunološkog sustava).
Sanofi-Aventis Deutschland GmbH
SANOFI-AVENTIS Zrt
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL - BOTTLE OF 30 TABLETS
NALJEPNICA - BOČICA S 30 TABLETA
• indigestion,
• probavne tegobe,
In case of constipation, please inform your doctor or pharmacist if you experience it.
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili ljekarnika.
The 0.4 g dose of Sevelamer carbonate Winthrop powder must be measured using the dosing spoon provided in the carton.
Winthrop praška mora se odmjeriti uporabom dozirne žličice koja je priložena u kutiji.
Sevelamer carbonate Winthrop is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease (CKD) not on dialysis with serum phosphorus ≥ 1.78 mmol/L.
Sevelamer carbonate Winthrop je indiciran i za kontrolu hiperfosfatemije u odraslih bolesnika s kroničnom bubrežnom bolešću koji nisu na dijalizi, a koji imaju razinu fosfora u serumu
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION • Periodic safety update reports (PSURs)
• Periodička izvješća o neškodljivosti lijeka (PSURevi)
INFORMATION IN BRAILLE 17.
15. UPUTE ZA UPORABU 16. PODACI NA BRAILLEOVOM PISMU
• stomach ache ,
• Opstrukcija crijeva
The standard dose is one tablet once a day.
Standardna doza je jedna tableta jednom na dan.
This medicine is the same as Azilect, which is already authorised in the European Union (EU).
Ovaj lijek isti je kao i Azilect, koji je već odobren u Europskoj uniji (EU).
The studies included 1,159 patients and lasted 26 and 18 weeks, respectively.
Ispitivanja su obuhvatila 1.159 bolesnika i trajala su 26, odnosno 18 tjedana.
Neurotransmitters are chemicals that allow nerve cells to communicate with one another.
Neurotransmiteri su kemikalije koje omogućuju međusobnu komunikaciju živčanih stanica.
The full EPAR and risk management plan summary for Rasagiline ratiopharm can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Razagilin ratiopharm nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
A fall in the UPDRS score indicates an improvement in symptoms, while a rise indicates a worsening of symptoms.
Smanjenje u vrijednosti UPDRS-a ukazuje na poboljšanje u simptomima, dok porast ukazuje na pogoršanje u simptomima.
Fluctuations happen when the effects of the medication wear off and symptoms reemerge.
Fluktuacije se događaju prilikom slabljenja djelovanja lijeka, a simptomi se ponovno pojavljuju.
In one of the studies, a 26-week treatment with Rasagiline ratiopharm resulted in an average fall of 0.13 points in UPDRS (a standard scale for assessing symptoms of Parkinson's disease) from a starting value of 24.69 compared with a rise of 4.07 points in the patients taking placebo from a starting value of 24.54.
U jednom od ispitivanja, 26-tjedna terapija lijekom Razagilin ratiopharm rezultirala je prosječnim smanjenjem od 0,13 poena u UPDRS-u (standardna skala za ocjenjivanje simptoma Parkinsonove bolesti) od standardne vrijednosti od 24,69 u usporedbi sa 4,07 poena u bolesnika koji su uzimali placebo od početne vrijednosti od 24,54.
They are linked to a reduction in the effect of levodopa, when the patient experiences sudden switches between being ‘on' and able to move, and being ‘off' and having difficulty moving about.
Isti su povezani sa smanjenjem u djelovanju levodopa, u slučaju kada bolesnik osjeća iznenadne promijene između „uključenog“ stanja i sposobnosti kretanja i „isključenog“ stanja i poteškoća prilikom kretanja.
In patients with Parkinson's disease, the cells that produce dopamine die and the amount of dopamine in the brain decreases.
U bolesnika s Parkinsonovom bolesti, stanice koje proizvode dopamin umiru, a količina dopamina u mozgu se smanjuje.
The European Commission granted a marketing authorisation valid throughout the European Union for Rasagiline ratiopharm on 12 January 2015.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Razagilin ratiopharm na snazi u Europskoj uniji od 12. siječnja 2015.
It blocks the enzyme monoamine oxidase type B, which breaks down the neurotransmitter dopamine in the brain.
Inhibira enzim monoaminooksidaze tipa B, koji razgrađuje neurotransmiter dopamin u mozgu.
Rasagiline ratiopharm is available as tablets (1 mg).
Razagilin ratiopharm dostupan je kao tablete (1 mg).
Similar reductions in time spent in the ‘off' state were seen in patients taking entacapone.
Slična smanjenja u vremenu provedenom u „isključenom“ stanju uočeno je u bolesnika koji su uzimali entakapon.
By increasing levels of dopamine in the parts of the brain that control movement and coordination, Rasagiline ratiopharm improves the signs and symptoms of Parkinson's disease, such as stiffness and slowness of movement.
Povećavajući razine dopamina u dijelovima mozga koji kontroliraju pokret i koordinaciju, Razagilin ratiopharm poboljšava znakove i simptome Parkinsonove bolesti, poput ukočenosti i usporenih pokreta.
It must also not be used with pethidine (a painkiller).
Ne smije se koristiti s petidinom (analgetikom).
In both studies, patients taking Rasagiline ratiopharm spent an average of around one hour less in the ‘off' state than those taking placebo.
U oba ispitivanja, bolesnici koji su uzimali Razagilin ratiopharm proveli su prosječno otprilike jedan sat manje u „isključenom“ stanju u odnosu na one koji su uzimali placebo.
There should be at least 14 days between stopping treatment with Rasagiline ratiopharm and starting treatment with another monoamine-oxidase inhibitor or with pethidine.
Treba proći najmanje 14 dana između završetka terapije lijekom Razagilin ratiopharm i početka liječenja drugim inhibitorom monoaminoksidaze ili petidinom.
The company that makes Azilect has agreed that its scientific data can be used for Rasagiline ratiopharm (‘informed consent').
Proizvođač lijeka Azilect pristao je da se njegovi znanstveni podaci koriste za lijek Razagilin ratiopharm (tzv. „informirani pristanak”).
This is a summary of the European public assessment report (EPAR) for Rasagiline ratiopharm.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Razagilin ratiopharm.
Patients with mild liver problems should use Rasagiline ratiopharm with caution and should stop treatment if their liver problems get worse.
Bolesnici s blagim problemima s jetrom trebaju oprezno koristiti Razagilin ratiopharm te trebaju prekinuti terapiju ako se problemi s jetrom pogoršaju.
Rasagiline ratiopharm is a medicine used to treat adults with Parkinson's disease (a progressive brain disorder that causes shaking, slow movement and muscle stiffness).
Razagilin ratiopharm je lijek koji se koristi za liječenje odraslih osoba s Parkinsonovom bolesti (progresivan poremećaj mozga koji uzrokuje drhtanje, usporene kretnje i krutost mišića).
The most common side effect with Rasagiline ratiopharm (seen in more than 1 patient in 10) is headache.
Najčešća nuspojava lijeka Razagilin ratiopharm (može se javiti u više od 1 na 10 osoba) je glavobolja.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Rasagiline ratiopharm, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Razagilin ratiopharm nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
The active substance in Rasagiline ratiopharm, rasagiline, is a ‘monoamine oxidase B inhibitor'.
Djelatna tvar lijeka Razagilin ratiopharm, razagilin, je „inhibitor monoaminooksidaze B“.
It is not intended to provide practical advice on how to use Rasagiline ratiopharm.
Svrha sažetka nije davati praktične savjete o korištenju lijeka Razagilin ratiopharm.
Rasagiline ratiopharm must not be used with other monoamine oxidase inhibitors including medicines and herbal preparations without prescription such as St John's wort (used to treat depression).
Razagilin ratiopharm ne smije se koristiti s drugim inhibitorima monoamineoksidaze, uključujući lijekove i biljne pripravke koji se izdaju bez liječničkog recepta poput gospine trave (koja se koristi za liječenje depresije).
In the two other studies, Rasagiline ratiopharm was given as ‘add-on' to patients with later stage disease who were already being treated with levodopa, and compared with placebo and another medicine entacapone (also used as add-ons).
U druga dva ispitivanja, Razagilin ratiopharm primijenjen je kao dodatna terapija u bolesnika s kasnijim stadijem bolesti koji su već liječeni levodopom, i uspoređen je s placebom i drugim lijekom entakaponom (koji se također koristi u dodatnim terapijama).
The Committee for Medicinal Products for Human Use (CHMP) decided that Rasagiline ratiopharm's benefits are greater than its risks and recommended that it be given marketing authorisation.
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Razagilin ratiopharm nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
What measures are being taken to ensure the safe and effective use of Rasagiline ratiopharm?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Razagilin ratiopharm?
Rasagiline ratiopharm must not be used in patients who have severe problems with their liver.
Razagilin ratiopharm ne smije se primjenjivati u bolesnika koji imaju ozbiljne probleme s jetrom.
Rasagiline ratiopharm has been shown in three studies, involving 1,563 patients, to be effective in both relieving the symptoms of Parkinson's disease and in reducing the time patients spend in their ‘off' periods.
U tri ispitivanja, koja su obuhvatila 1.563 bolesnika, utvrđeno je da je Razagilin ratiopharm djelotvoran u ublažavanju simptoma Parkinsonove bolesti, te u skraćivanju vremena kojeg bolesnici provedu u „isključenom“ stanju.
For more information about treatment with Rasagiline ratiopharm, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Razagilin ratiopharm pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku.
Rasagiline ratiopharm can be used either alone, or as an add-on to levodopa (another medicine used in Parkinson's disease) in patients who are having ‘fluctuations' towards the end of the period between levodopa doses.
Razagilin ratiopharm može se koristiti kao monoterapija ili kao dodatna terapija s levodopom (drugim lijekom koji se koristi za liječenje Parkinsonove bolesti) u bolesnika s „fluktuacijama“ prilikom isteka razdoblja između doza levodopa.
A risk management plan has been developed to ensure that Rasagiline ratiopharm is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Razagilin ratiopharm.
Why is Rasagiline ratiopharm approved?
Zašto je Razagilin ratiopharm odobren?
Other information about Rasagiline ratiopharm
Ostale informacije o lijeku Razagilin ratiopharm
Rasagiline ratiopharm rasagiline
Razagilin ratiopharm razagilin
What is Rasagiline ratiopharm and what is it used for?
Što je Razagilin ratiopharm i za što se koristi?
For practical information about using Rasagiline ratiopharm, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o korištenju lijeka Razagilin ratiopharm pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
Rasagiline ratiopharm contains the active substance rasagiline.
Razagilin ratiopharm sadrži djelatnu tvar razagilin.
What are the risks associated with Rasagiline ratiopharm?
Koji su rizici povezani s lijekom Razagilin ratiopharm?
For the full list of all side effects and restrictions with Rasagiline ratiopharm, see the package leaflet.
Potpuni popis svih nuspojava i ograničenja s lijekom Razagilin ratiopharm potražite u uputi o lijeku.
How is Rasagiline ratiopharm used?
Kako se Razagilin ratiopharm koristi?
What benefits of Rasagiline ratiopharm have been shown in studies?
Koje su koristi lijeka Razagilin ratiopharm utvrđene u ispitivanjima?
For the full list of all side effects reported with Rasagiline ratiopharm, see the package leaflet.
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Razagilin ratiopharm potražite u uputi o lijeku.
How does Rasagiline ratiopharm work?
Kako djeluje Razagilin ratiopharm?
Further information on Cortacare can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Više informacija o VMP-u Cortacare nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Cortacare (hydrocortisone aceponate)
Cortacare (hidrokortizon aceponat)
This reduces swelling, redness and itching.
To smanjuje oticanje, crvenilo i svrbež.
As for every medicine, the company provided studies on the quality of Cortacare.
Kao i za svaki lijek, tvrtka je dostavila ispitivanja o kvaliteti lijeka Cortacare.
Cortacare received a marketing authorisation valid throughout the EU on 27 August 2018.
VMP Cortacare dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 27. kolovoza 2018.
Cortacare is a ‘hybrid medicine'.
Cortacare je „hibridni lijek”.
Cortacare is sprayed onto the affected area of skin at a distance of about 10 cm once daily for a week.
Cortacare se treba raspršiti na zahvaćeno područje kože s udaljenosti od 10 cm jednom dnevno tjedan dana.
What is Cortacare and what is it used for?
Što je Cortacare i za što se primjenjuje?
An overview of Cortacare and why it is authorised in the EU
Pregled informacija o lijeku Cortacare i zašto je odobren u EU-u
The European Medicines Agency concluded that, in accordance with EU requirements, Cortacare has been shown to be comparable to Cortavance.
Europska agencija za lijekove zaključila je kako je, u skladu sa zahtjevima EU-a, utvrđeno da je VMP Cortacare usporediv s VMP-om Cortavance.
It contains the active substance hydrocortisone aceponate.
Sadrži djelatnu tvar hidrokortizon aceponat.
The hydrocortisone in Cortacare is in a special chemical form (di-ester) so the medicine is able to get into the outer layer of the skin and remain there for longer.
Hidrokortizon je u VMP-u Cortacare prisutan u posebnom kemijskom obliku (di-ester) tako da lijek može prodrijeti u vanjski dio kože i ondje ostati dulje vremena.
There was no need for ‘bioequivalence' studies to investigate whether Cortacare is absorbed similarly to the reference medicine to produce the same level of the active substance in the blood.
Nisu bila potrebna ispitivanja „bioekvivalencije” kako bi se istražilo apsorbira li se VMP Cortacare slično referentnom lijeku kako bi doveo do iste razine djelatne tvari u krvi.
Cortacare is a corticosteroid veterinary medicine used to treat inflamed and itchy skin conditions in dogs.
Cortacare je veterinarsko-medicinski kortikosteroid koji se koristi za liječenje upaljene kože i svrbeža u pasa.
This makes the medicine more effective at low doses in skin conditions.
Stoga su manje doze lijeka djelotvornije za stanja kože.
What are the benefits and risks of Cortacare?
Koje su koristi i rizici od VMP-a Cortacare?
Studies on the benefits and risks of the active substance in the authorised use have already been carried out with the reference medicine, Cortavance, and do not need to be repeated for Cortacare.
Ispitivanja koristi i rizika od djelatne tvari u odobrenoj primjeni već su provedena s referentnim VMPom Cortacare i stoga ih nije potrebno ponavljati za VMP Cortacare.
Other information about Cortacare
Ostale informacije o lijeku Cortacare
The active substance in Cortacare, hydrocortisone aceponate, is a corticosteroid or ‘steroid' which acts in the skin cells by stopping the release of chemicals which are involved in inflammation.
Djelatna tvar u VMP-u Cortacare, hidrokortizon aceponat je kortikosteroid ili „steroid” koji djeluje u stanicama kože tako da zaustavlja otpuštanje kemikalija koje su uključene u upalni proces.
composition of Cortacare is the same as the reference medicine and when sprayed onto the skin, the active substance in both products is expected to be absorbed in the same way.
kao i kod referentnog lijeka i, kada se primjenjuje raspršivanjem na kožu, očekuje se da se djelatna tvar kod oba lijeka apsorbira na isti način.
Therefore, the Agency's view was that, as for Cortavance, the benefit of Cortacare outweighs the identified risk and it can be authorised for use in the EU.
Stoga je stav Agencije da korist od VMP-a Cortacare, kao i od VMP-a Cortavance, nadmašuje identificirani rizik te da lijek može biti odobren za primjenu u EU-u.
Why is Cortacare authorised in the EU?
Zašto je VMP Cortacare odobren u EU-u?
Because Cortacare is a hybrid medicine, its benefits and risks are taken as being the same as the reference medicine's.
Budući da je Cortacare hibridni VMP, smatra se da su njegove koristi i rizici jednaki onima utvrđenima za referentni VMP.
Two sprays is sufficient to treat an area of skin 10 cm by 10 cm. Care should be taken to avoid spraying the eyes of the dog.
Dva raspršivanja dovoljna su za liječenje područja kože veličine 10 cm puta 10 cm.